Literature DB >> 29289990

Prevalence, clinical characteristics, and reproductive outcomes of polycystic ovary syndrome in older women referred for tertiary fertility care.

Samer Tannus1, Justin Tan2, Weon-Young Son3, Michael-Haim Dahan3.   

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive age women. The clinical symptoms of PCOS vary with female age, as older women tend to have lower hyperandrogenic symptoms and many regain regular cycles. In this study, we aimed to estimate the prevalence of PCOS among older women referred for fertility care, describe their clinical characteristics, and compare their reproductive outcomes to those of matched control group.
METHODS: A retrospective study conducted at a single reproductive center. All women aged ≥ 40, who were referred for in-vitro fertilization (IVF), between the years 2011-2015 were screened for possible inclusion. The PCOS diagnosis (was) made based on the Rotterdam criteria. The reproductive outcomes of the PCOS group were compared to those of matched control with tubal infertility.
RESULTS: During the study period, 1427 women, aged 40 years and over, underwent a total of 2124 IVF cycles. Of these, 72 (5%) women were diagnosed with PCOS. In 69 (95.6%), the PCOS diagnosis was made by a combination of polycystic ovary morphology (PCOM) and anovulation. Compared to women with tubal factor infertility, women with PCOS needed lower doses of gonadotropins, had higher number of retrieved oocytes (16.6 vs. 10.4) and higher number of cycles with embryo cryopreservation (47 vs. 22.9%). This resulted in higher cumulative live birth in the PCOS group (26.3 vs. 15.2%, p = 0.04).
CONCLUSION: PCOS comprised 5% of the infertility diagnosis in women aged ≥ 40; PCOM and anovulation were the most prominent features. The higher oocyte number resulted in improved cumulative live birth rate.

Entities:  

Keywords:  Advanced maternal age; Cumulative live birth rate; In-vitro fertilization; Oocytes; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2017        PMID: 29289990     DOI: 10.1007/s00404-017-4642-z

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

Review 1.  Effects of Vitamin D on Fertility, Pregnancy and Polycystic Ovary Syndrome-A Review.

Authors:  Szabolcs Várbíró; István Takács; László Tűű; Katalin Nas; Réka Eszter Sziva; Judit Réka Hetthéssy; Marianna Török
Journal:  Nutrients       Date:  2022-04-15       Impact factor: 6.706

2.  The Effect of Age on IVF-ET Outcome in Infertile Patients with PCOS Based on Tiangui Theory in Chinese Medicine.

Authors:  Hui Chang; Jian Li; Qi Wu; Xin Fu; Mengyi Zhu; Hang Ge; Baichao Shi; Xiaoguang Shao; Yanhua Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-22       Impact factor: 2.650

3.  Influence of Maternal Age and Ovarian Reserve on the Decision to Continue or to Cancel IVF Cycles in Patients with One or Two Large Follicles: a Dual Effect.

Authors:  Guy Shrem; Mali Salmon-Divon; Alina M Mahfoudh; Jacques Balayla; Alexander Volodarsky-Perel; Sara Henderson; Atif Zeadna; Weon-Young Son; Naama Steiner; Michael H Dahan
Journal:  Reprod Sci       Date:  2021-06-11       Impact factor: 3.060

4.  Infertility management in primary care.

Authors:  Angela Thable; Elsie Duff; Cheryl Dika
Journal:  Nurse Pract       Date:  2020-05

5.  A Slower Age-Related Decline in Treatment Outcomes After the First Ovarian Stimulation for in vitro Fertilization in Women With Polycystic Ovary Syndrome.

Authors:  Jing Li; Xiaocong Liu; Linli Hu; Fuli Zhang; Fang Wang; Huijuan Kong; Shanjun Dai; Yihong Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-05       Impact factor: 5.555

6.  Independent Variables for Determining the Cumulative Live Birth Rates of Aged Patients with Polycystic Ovary Syndrome or Tubal Factor Infertility: A Retrospective Cohort Study.

Authors:  Yichun Guan; Pingping Kong; Zhiying Xiao; Junyan Zhang; Jingfang He; Wenjun Geng; Junfang Yan; Simin Sun; Mingkun Mu; Xiaofang Du; Xingling Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-17       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.